Valeant (VRX) intends to its improve its $45.7B offer for Allergan (AGN) based of feedback that the Canadian company hopes to receive from Allergan shareholders during a Webcast about the deal on May 28.
"We are prepared to pay a full and fair price, but, consistent with our track record, we will remain financially disciplined," Valeant said.
The firm's comments come after Allergan formally rejected Valeant's proposal yesterday.
Allergan's shares are +1.9% premarket. (PR)